Therapeutics News and Research

RSS

ALLOZYNE signs worldwide licensing agreement with The Scripps Research Institute

ALLOZYNE Inc. announced today the signing of a worldwide licensing agreement with The Scripps Research Institute. The agreement gives ALLOZYNE rights to a unique and powerful chemical reaction, developed by Nobel Laureate K. Barry Sharpless of Scripps Research, known as "Click chemistry." The novelty of this reaction comes from its ability to introduce two different molecular components and have them "click" together stably and irreversibly.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

PharmSource ranks Patheon as top global contract development and manufacturing organization

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Efforts to raise disease awareness in the Philippines have increased the number of cases and patient pool available for hepatitis C treatment. Screening and detection efforts by the Red Cross as well as growing awareness in the Philippines have been largely responsible for the rise in the number of diagnosed cases. These campaigns have encouraged people, mostly from the urban areas, to opt for physical examinations that enable the detection of hepatitis C.

15 Jul 2010

Scientists awarded $2.3M grant to develop new treatments for drug addiction

A pair of scientists on the Florida campus of The Scripps Research Institute has been awarded a $2.3 million grant by the National Institutes of Health to conduct research relevant to developing new treatments for drug addiction.

15 Jul 2010

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

$Osseon receives notice of allowance for spinal vertebral compression fracture technology$

Osseon receives notice of allowance for spinal vertebral compression fracture technology

Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, today received a notice of allowance for its spinal vertebral compression fracture (VCF) technology. The company which was started in 2006 has thirteen additional patent applications pending in the United States and throughout the world for related spinal therapies and devices. The lead inventor for this inaugural patent is Dr. Y. King Liu, one of three founders of Osseon.

15 Jul 2010

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Aestus Therapeutics, Inc. announced today a collaboration agreement with Eisai Inc. on research and development of novel therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will entail pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.

15 Jul 2010

NIAID awards ATCC multimillion dollar MID-BRR contract

ATCC, the premier biological materials resource, services, and standards organization, has been awarded the National Institute of Allergy and Infectious Diseases, Microbiology and Infectious Diseases Biological Resource Repository ("MID-BRR") contract, ATCC announced today. The current value of the contract is $14,615,598 with the ultimate value of $115,733,409 over 7 years with an annual renewal.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Invida Group, Amdipharm partner to promote proprietary products in key Asian markets

Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into an agreement with Amdipharm for the licensing and commercialization of its proprietary products throughout Asia. Under this agreement, Invida will leverage its full suite of capabilities to bring Amdipharm's products to market, from regulatory approval and licensing, through packaging and supply chain optimization, to commercialization, sales, and marketing.

14 Jul 2010

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

Silence Therapeutics plc is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.

14 Jul 2010

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

Cell Therapeutics today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences S.r.l. for CTI's drug candidate pixantrone.

14 Jul 2010

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced that it was awarded an Advanced Technology Small Business Innovation Research grant by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

13 Jul 2010

Anika to defend patent infringement lawsuit for MONOVISC product

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation.

13 Jul 2010

BioMimetic announces common stock public offering

BioMimetic Therapeutics, Inc. announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

13 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas.

12 Jul 2010

Therapeutics News and Research

ALLOZYNE signs worldwide licensing agreement with The Scripps Research Institute

NIH awards MacroGenics $9.8 million grant for three projects

PharmSource ranks Patheon as top global contract development and manufacturing organization

Activities of TAT fully consolidated into Geron

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Scientists awarded $2.3M grant to develop new treatments for drug addiction

Aduro BioTech announces issuance of two important patents

Osseon receives notice of allowance for spinal vertebral compression fracture technology

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

NIAID awards ATCC multimillion dollar MID-BRR contract

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Invida Group, Amdipharm partner to promote proprietary products in key Asian markets

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

CTI signs agreement with NerPharMa for long-term manufacture of pixantrone

RXi Pharmaceuticals receives SBIR grant to further develop novel RNAi therapeutics

Anika to defend patent infringement lawsuit for MONOVISC product

BioMimetic announces common stock public offering

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News